Open AccessIncretin manipulation in diabetes management
Author(s) -
Joseph M Pappachan,
Arkiath Veettil Raveendran,
Rajagopalan Sriraman
Publication year - 2015
Publication title -
world journal of diabetes
Language(s) - Uncategorized
Resource type - Journals
ISSN - 1948-9358
DOI - 10.4239/wjd.v6.i6.774
Subject(s) - medicine , incretin , exenatide , diabetes mellitus , hypoglycemia , sitagliptin , tolerability , type 2 diabetes mellitus , type 2 diabetes , diabetes management , glucagon like peptide 1 , pharmacology , intensive care medicine , endocrinology , adverse effect
Incretin-based therapies have revolutionized the medical management of type 2 diabetes mellitus (T2DM) in the 21(st) century. Glucagon-like peptide-1 (GLP-1) suppresses appetite and gastric motility, and has trophic effects on pancreas, cardio-protective and renal effects. GLP-1 analogues and dipeptidyl peptidase-4 inhibitors form the incretin-based therapies. Significant reduction of hemoglobin A1c when used as monotherapy and in combination regimens, favorable effects on body weight, and low risk of hypoglycemia are their unique therapeutic benefits. Their safety and tolerability are comparable to other anti-diabetic medications. Concern about elevated risk of pancreatitis has been discarded by two recent meta-analyses. This article discusses the therapeutic manipulation of incretin system for the management of T2DM.